Nova Eye Medical EYE.AX · AUD

Its shares trade on ASX under the ticker EYE.AX. It has been listed since 12 October 1987. In the fiscal year to 30 June 2026, it reported revenue of A$34.9m and a net loss of A$4.3m. At that date it held total assets of A$21.6m and shareholders' equity of A$14.3m.

Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia. The firm develops, manufactures and sells a portfolio of ophthalmic treatment technologies and devices. Its technologies include iTrack minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye. The Molteno3 glaucoma drainage device platform is designed to manage surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control. The company also provides retinal rejuvenation therapy (2RT) laser technology as a therapy for patients with intermediate age-related macular degeneration.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Victor PrevinExecutive Chairman of the Board, since 2001A$220,141
• Mr. Thomas SpurlingManaging Director, Executive Director, since 2011A$310,578
• Mr. Simon GrayCompany Secretary
• Mr. Michael SouthardNon-Executive Director, since 2018A$41,697
• Mr. Daniel WebbIndependent Director
• Mr. Rahmon CoupeNon-Executive Independent DirectorA$44,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.